Navigation Links
Nile Therapeutics Reports 2011 Third Quarter Financial Results
Date:11/14/2011

SAN MATEO, Calif., Nov. 14, 2011 /PRNewswire/ -- Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced its third quarter financial results for 2011.

Financial ResultsFor third quarter of 2011, Nile reported research and development collaboration income relating to its cenderitide program of approximately $0.8 million, as compared to none in the third quarter of 2010. The net loss for the third quarter of 2011 was approximately $1.1 million, or $0.03 per share, compared to a net loss of approximately $1.8 million, or $0.05 per share, during the third quarter of 2010. Weighted-average shares outstanding for the third quarter of 2011 were 39.7 million.

Net cash used in operating activities in the third quarter of 2011 was approximately $0.7 million. As of September 30, 2011, Nile had cash and cash equivalents of approximately $2.6 million compared to approximately $3.4 million as of December 31, 2010.

Update on CenderitideIn October 2011, Nile completed patient dosing of an open-label Phase I clinical trial evaluating pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of subcutaneous bolus and subcutaneous infusion of cenderitide in patients with chronic heart failure. The trial was an important step towards developing cenderitide as a 90-day outpatient treatment for heart failure patients following admission for acutely decompensated heart failure (ADHF), referred to as the "post-acute" treatment period.

The Phase I clinical trial was designed to evaluate the required dosage to achieve pre-determined plasma levels of cenderitide when delivered through a subcutaneous infusion pump. In Part A of the trial, 12 patients received two subcutaneous bolus injections of cenderitide.  In Part B of the trial, 34 patients received a 24-hour continuous subcutaneous infusion of either of two fixed doses of cenderitide or placebo. In
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
2. Orexigen® Therapeutics Reports Third Quarter Financial Results
3. Silence Therapeutics Provides Corporate and Development Update
4. Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
5. Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 2011
6. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
7. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
8. United Therapeutics Corporation Reports Third Quarter 2011 Financial Results
9. Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline
10. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
11. DLVR Therapeutics Inc. Raises Additional Capital Adding MaRS Innovation to Investor Base
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... (PRWEB) August 21, 2014 DNA vaccine ... progress in its development of JRC-LAMP-vax, an innovative and ... pollen. Phase IC studies began this month in Hawaii, ... hay fever. , The Japanese red cedar releases pollen ... in Japan. Mountain Cedar pollen wreaks similar havoc in ...
(Date:8/21/2014)... His Majesty Willem-Alexander, King of the ... of His Majesty Willem-Alexander, King of the Netherlands, has ... of POET-DSM Advanced Biofuels’ Project LIBERTY cellulosic ethanol plant ... King will take part in the Grand Opening Ceremony ... a.m.-12:20 p.m. and tour the plant. POET-DSM is a ...
(Date:8/21/2014)... Aug. 21, 2014 OTC Markets ... Inc., a biotechnology company, on its approval to ... traded on OTCQX®, the best marketplace for established ... Group. Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... successful execution of its growth strategy and achievement ...
(Date:8/21/2014)... MO (PRWEB) August 21, 2014 ... service biopharmaceutical contract development and manufacturing organization (CMO) ... Progenics Pharmaceuticals, Inc., an oncology company focused on ... treating cancer, to manufacture the anti-prostate specific membrane ... ADC product candidate. Under the agreement the ...
Breaking Biology Technology:Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3
... LOS ANGELES, May 3, 2012 MD+DI ... UBM Canon,s leading brand providing the medical device industry with ... a 2012 Maggie Award for Best Overall Category in the ... 2011 issue. MD+DI,s May 2011 cover ...
... PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) ... 31, 2012. (Logo:  http://photos.prnewswire.com/prnh/20110822/SF55808LOGO ) ... percent over the same period of 2011. Total revenues for ... $83.3 million for the same period of 2011. Total revenue ...
... May 3, 2012 Immunomic Therapeutics, Inc., ("ITI," Lancaster, ... MD, announced that the U.S. Food and Drug Administration ... Drug Application ("IND") filed for the allergy immunotherapy, JRC- ... ITI that there will be no clinical hold and ...
Cached Biology Technology:MD+DI, the Global MedTech Industry Authority, Wins a 2012 Maggie for Best Overall Category in Medical, Dental & Related Services/Trade 2PDL BioPharma Announces First Quarter 2012 Financial Results 2PDL BioPharma Announces First Quarter 2012 Financial Results 3PDL BioPharma Announces First Quarter 2012 Financial Results 4PDL BioPharma Announces First Quarter 2012 Financial Results 5Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRC-LAMP-Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy 2Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRC-LAMP-Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy 3
(Date:8/22/2014)... is available in German . ... in PCFs proteins are fixated in a way so ... Next, the HZB and Fudan University researchers are planning ... functional materials. Their findings are being published today in ... , Proteins are sensitive molecules. Everyone knows that ...
(Date:8/22/2014)... American consumers will finally be able to purchase fuel ... as zero-emissions vehicles, most of the cars will run ... that contributes to global warming. , Now scientists at ... uses an ordinary AAA battery to produce hydrogen by ... through two electrodes that split liquid water into hydrogen ...
(Date:8/21/2014)... -- A new study of American singles found ... have the highest orgasm rates. On average, men ... their sexual orientation making little difference. For women, ... women experience orgasm 62.9 percent of the time ... this pattern varies with women,s sexual orientation, with ...
Breaking Biology News(10 mins):Proteins: New class of materials discovered 2Stanford scientists develop a water splitter that runs on an ordinary AAA battery 2Stanford scientists develop a water splitter that runs on an ordinary AAA battery 3Orgasm rates for single women less predictable than men's, vary by sexual orientation 2Orgasm rates for single women less predictable than men's, vary by sexual orientation 3Orgasm rates for single women less predictable than men's, vary by sexual orientation 4
... - (Toronto) A new study from the Centre for ... a variation of a specific gene may play a role ... of Alzheimer,s cases. This innovative study has combined genetics and ... developing late-onset Alzheimer,s disease long before symptoms appear. The ...
... examine the response to noise of a diverse range of ... found that many families of crustaceans previously assumed to be ... Lizard Island on the Great Barrier Reef, the team collected ... webs. On each of 34 nights, one light trap ...
... (Minority Access to Research Careers) Program has announced the ... Sports Medicine (ACSM) Southeast Chapter Annual Meeting in Greenville, ... to promote the entry of underrepresented minority students, postdoctorates ... community and to encourage the participation of young scientists ...
Cached Biology News:Combining brain imaging, genetic analysis may help identify people at early risk of Alzheimer's 2Rowdy residents warn crustaceans away from perilous reefs 2
... The Label IT siRNA Tracker ... Reagent provides a straight forward approach ... of your design, in an efficient ... tracking experiments. Subcellular localization and functional ...
... (A) and 36kDa (C) subunits Formulation: ... 500mM NaCl, 60mM 2-mercaptoethanol, 1mM MgCl2, ... and 0.1mg/ml serum albumin Properites: For ... Purification: DEAE chromatography, aminohexyl-agarose and gel ...
... IT siRNA Tracker Intracellular Localization Kit ... straight forward approach to directly label ... in an efficient yet non-destructive manner, ... localization and functional inhibition of target ...
... The Label IT siRNA Tracker Intracellular ... provides a straight forward approach to ... your design, in an efficient yet ... experiments. Subcellular localization and functional inhibition ...
Biology Products: